The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of durable hematocrit control and minimal thrombotic risk in real-world polycythemia vera patients treated with ruxolitinib.
 
Aleksander Lech Chojecki
Honoraria - Research to Practice
Consulting or Advisory Role - MorphoSys; Novartis; SERVIER
Research Funding - Incyte (Inst)
 
Danielle Boselli
No Relationships to Disclose
 
Allison Dortilus
No Relationships to Disclose
 
Issam Hamadeh
No Relationships to Disclose
 
Stephanie Begley
No Relationships to Disclose
 
Tommy Chen
No Relationships to Disclose
 
Rupali Bose
Honoraria - Abbvie (I); Adaptive Biotechnologies (I); ADC Therapeutics (I); AstraZeneca (I); Bristol-Myers Squibb (I); Epizyme (I); Genmab (I); Gilead Sciences (I); Janssen Oncology (I); Karyopharm Therapeutics (I); Loxo/Lilly (I); Roche/Genentech (I); Seagen (I); TG Therapeutics (I)
Consulting or Advisory Role - Abbvie (I); Adaptive Biotechnologies (I); ADC Therapeutics (I); AstraZeneca (I); Bristol-Myers Squibb (I); Epizyme (I); Genmab (I); Gilead Sciences (I); Janssen Oncology (I); Karyopharm Therapeutics (I); Loxo/Lilly (I); Roche/Genentech (I); Seagen (I); TG Therapeutics (I)
Speakers' Bureau - Abbvie (I); AstraZeneca (I); Bristol-Myers Squibb (I); Epizyme (I); Gilead Sciences (I); Janssen Oncology (I)
Research Funding - Bristol-Myers Squibb (I); Genentech (I); Gilead Sciences (I); TG Therapeutics (I)
 
Nikolai Alexandrovich Podoltsev
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Constellation Pharmaceuticals; CTI BioPharma Corp; Incyte; Novartis; Pharmaessentia
Research Funding - AI Therapeutics (Inst); Arog (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Jazz Pharmaceuticals (Inst); Kartos Therapeutics (Inst); Pfizer (Inst); Samus Therapeutics (Inst); Sunesis Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Incyte
Other Relationship - Syneos Health
 
Amer Methqal Zeidan
Honoraria - Abbvie; Acceleron Pharma; Agios; Astellas Pharma; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Daiichi Sankyo; Epizyme; Geron; Ionis Pharmaceuticals; Jazz Pharmaceuticals; Novartis; Otsuka; Pfizer; Seagen; Taiho Pharmaceutical; Takeda; Trovagene
Consulting or Advisory Role - Abbvie; Acceleron Pharma; Agios; Astellas Pharma; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Epizyme; Geron; Incyte; Ionis Pharmaceuticals; Jazz Pharmaceuticals; Novartis; Otsuka; Pfizer; Seagen; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Aprea AB (Inst); Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst); Trovagene (Inst)
Travel, Accommodations, Expenses - Celgene; Novartis; Pfizer; Trovagene
 
Nicole Baranda Balmaceda
No Relationships to Disclose
 
Abdulraheem Yacoub
Consulting or Advisory Role - Abbvie; Acceleron Pharma; CTI BioPharma Corp; Gilead Sciences; Incyte; notab; Novartis; Pfizer; Pharmaessentia; SERVIER
 
Jing Ai
No Relationships to Disclose
 
Thomas Gregory Knight
No Relationships to Disclose
 
Brittany K. Ragon
No Relationships to Disclose
 
Nilay Arvind Shah
Speakers' Bureau - Bristol Myers Squibb; Incyte
 
Srinivasa Sanikommu
No Relationships to Disclose
 
James Thomas Symanowski
Consulting or Advisory Role - Astellas Pharma; Camurus; CARsgen Therapeutics; Endocyte (Inst); Immatics; Lilly
Research Funding - Various (Inst)
 
Ruben A. Mesa
Consulting or Advisory Role - Constellation Pharmaceuticals; La Jolla Pharma; Novartis; Sierra Oncology
Research Funding - Abbvie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Genentech (Inst); Incyte (Inst); Mays Cancer Center (Inst); NCI (Inst); Promedior (Inst); Samus (Inst)
 
Michael Richard Grunwald
Stock and Other Ownership Interests - Medtronic
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Blueprint Medicines; Bristol-Myers Squibb; Cardinal Health; CTI BioPharma Corp; Daiichi Sankyo; Gamida Cell; Genentech; Genentech; Gilead Sciences; GlaxoSmithKline/Sierra Oncology; Incyte; InVitae; Jazz Pharmaceuticals; Novartis; Ono Pharmaceutical; Pfizer; Pharmacosmos; Premier, Inc.; SERVIER; Stemline Therapeutics
Research Funding - Incyte (Inst); Janssen (Inst)